The Recombinant Human CCL25/TECK Protein is a biologically active recombinant protein that plays a significant role in various cellular processes and signaling pathways in human biology. This protein is widely employed in immunological research, cell biology studies, protein-protein interaction analyses, and therapeutic development, providing researchers with a reliable tool for investigating CCL25/TECK function and its implications in health and disease.
This product (SKU: RPCB0017) is produced using advanced expression systems and features a C-His tag for convenient detection and purification. The protein exhibits a calculated molecular weight of 15.01 kDa with an observed molecular weight of 20-25 kDa under denaturing conditions, achieving ≥ 90 % as determined by SDS-PAGE., ensuring exceptional quality and consistency for research applications.
High quality, high purity and low endotoxin recombinant Recombinant Human CCL25/TECK Protein (RPCB0017), tested reactivity in HEK293 cells and has been validated in SDS-PAGE.100% guaranteed.
Endotoxin:
< 0.1 EU/μg of the protein by LAL method.
Purity:
≥ 90 % as determined by SDS-PAGE.
Formulation:
Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.
Reconstitution:
Centrifμge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.
Storage:
Store at -20℃. Store the lyophilized protein at -20℃ to -80℃ up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.
CCL25, also known as TECK, is a CC chemokine that regulates the trafficking of lymphocytes in the thymus and small intestine. Mature human CCL25 shares 40% amino acid sequence identity with mouse and rat CCL25. CCL25 is produced by stromal cells in the thymus and epithelial cells of the small intestine, particularly the jejunum and ileum. It binds to and induces chemoattraction through CCR9, and both human and mouse proteins act on human CCR9. CCR9 is expressed on immature pre-T cells and thymocytes. In cancer, functional CCR9 mediates the metastasis of melanoma cells to the small intestine, contributes to the CCL25-dependent migration and invasion of some breast carcinomas, and attracts mesenchymal stromal cells to CCL25-expressing multiple myelomas. CCL25 contributes to the severity of chronic inflammation in rheumatoid arthritis where it attracts CCR9+ monocytes and macrophages, in endometriosis where it promotes the invasiveness of stromal cells, and in atherosclerosis where it contributes to the accumulation of CCR9+ macrophages in arterial plaques.
Recombinant Human CCL25/TECK Protein was determined by SDS-PAGE under reducing conditions with Coomassie Blue.
